



HAL
open science

The ‘Peptide for Life’ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe

Antoni Bayes-Genis, James L Januzzi, A. Mark Richards, Henrike Arfsten, Rudolf A Boer, Michele Emdin, Arantxa González, Tiny Jaarsma, Pardeep S Jhund, Christian Mueller, et al.

► To cite this version:

Antoni Bayes-Genis, James L Januzzi, A. Mark Richards, Henrike Arfsten, Rudolf A Boer, et al.. The ‘Peptide for Life’ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. *European Journal of Heart Failure*, 2021, 23 (9), pp.1432-1436. 10.1002/ejhf.2293 . hal-03754129

HAL Id: hal-03754129

<https://hal.univ-lorraine.fr/hal-03754129v1>

Submitted on 19 Aug 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The Peptide for Life Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe

Antoni Bayes-Genis, James L. Januzzi, A. Mark Richards, Henrike Arfsten, Rudolf A. de Boer, Michele Emdin, Arantxa Gonzalez, Tiny Jaarsma, Pardeep S. Jhund, Christian Mueller, Julio Nunez, Patrick Rossignol, Ivan Milinkovic, Giuseppe M. C. Rosano, Andrew Coats and Petar Seferovic

The self-archived postprint version of this journal article is available at Linköping University Institutional Repository (DiVA):

<http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-179961>

N.B.: When citing this work, cite the original publication.

Bayes-Genis, A., Januzzi, J. L., Richards, A. M., Arfsten, H., de Boer, R. A., Emdin, M., Gonzalez, A., Jaarsma, T., Jhund, P. S., Mueller, C., Nunez, J., Rossignol, P., Milinkovic, I., Rosano, G. M. C., Coats, A., Seferovic, P., (2021), The Peptide for Life Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe, *European Journal of Heart Failure*, 23(9), 1432-1436. <https://doi.org/10.1002/ejhf.2293>

Original publication available at:

<https://doi.org/10.1002/ejhf.2293>

Copyright: Oxford University Press

<http://www.oxfordjournals.org/>



**The “Peptide for Life” Initiative:
A Call for Action to Provide Equal Access for the Use of Natriuretic Peptides in
the Diagnosis of Acute Heart Failure across Europe**

Antoni Bayes-Genis^{1,2}, James L Januzzi^{3,4,5}, A Mark Richards^{6,7}, Henrike Arfsten⁸,
Rudolf A de Boer⁹, Michele Emdin^{10,11}, Arantxa Gonzalez^{2,12}, Tiny Jaarsma¹³, Pardeep
S Jhund¹⁴, Christian Mueller¹⁵, Julio Núñez^{2,16}, Patrick Rossignol¹⁷, Ivan Milinkovic¹⁸
Giuseppe MC Rosano¹⁹, Andrew Coats^{20,21}, Petar Seferovic^{18,22}

From:

¹Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain;
²CIBERCV, Instituto de Salud Carlos III, Madrid, Spain; ³Massachusetts General
Hospital, Boston, MA, USA. ⁴Harvard Medical School, Boston, MA, USA. ⁵Baim
Institute for Clinical Research, Boston, MA, USA. ⁶Cardiac Department, National
University Hospital, Cardiovascular Research Institute, National University Heart
Centre, National University Health System, Singapore. ⁷Christchurch Heart Institute,
University of Otago, NZ. ⁸Department of Internal Medicine II, Division of Cardiology,
Medical University of Vienna, Waehringerguertel 18-20, Vienna, 1090, Austria.
⁹University Medical Center Groningen, University of Groningen, Department of
Cardiology, Groningen, The Netherlands. ¹⁰Institute of Life Sciences, Scuola Superiore
Sant’Anna, Pisa, Italy. ¹¹Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
¹²Program of Cardiovascular Diseases, CIMA Universidad de Navarra, and Navarra
Institute for Health Research (IdiSNA) Pamplona, CIBERCV, Spain. ¹³Division of
Nursing Sciences and Reproductive Health, Department of Health, Medicine and Caring
Sciences, Linköping University, SE-581 83 Linköping, Sweden. ¹⁴BHF Cardiovascular
Research Centre, University of Glasgow, Glasgow, United Kingdom. ¹⁵Department of
Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital
Basel, University of Basel, Basel, Switzerland. ¹⁶Servicio de Cardiología, Hospital
Clínico Universitario. INCLIVA. Universitat de Valencia. Valencia-Spain. ¹⁷ Université
de Lorraine, Centre d’Investigation Clinique Plurithématique 1433, Inserm U1116,
CHRU de Nancy, F-CRIN INI-CRCT Network, Nancy, France. ¹⁸Faculty of Medicine,
University of Belgrade, Belgrade, Serbia. ¹⁹University and IRCCS San Raffaele Roma.

²⁰Monash University, Melbourne, Australia.²¹University of Warwick, Coventry, UK.

²²Serbian Academy of Sciences and Arts, Belgrade, Serbia.

Funding: None.

Word count (without references): 1497

***Corresponding Author:**

Antoni Bayes-Genis, MD, PhD, FESC, FHFA.

Head, Heart Institute. Hospital Universitari Germans Trias i Pujol.

Carretera de Canyet s/n 08916. Badalona (Barcelona), Spain.

E-mail: abayesgenis@gmail.com.

The Breathing Not Properly (BNP) study, published in 2002, kick-started the use of natriuretic peptides (NPs) as companion biomarkers for the diagnosis of heart failure (HF)(1). More than just a clinical trial with positive results, it revolutionized a whole field and introduced biomarkers and the molecular phenotyping of the heart to algorithms in use for HF diagnosis and management. Ever since, the use of biomarkers to predict the onset of future HF, identify its presence when fully developed, and risk-stratify affected patients has gathered much attention and inspired a tsunami of studies. Indeed, the introduction of objective, non-invasive, biologically meaningful biomarkers to clinical assessment has considerably changed the way HF is diagnosed and monitored (2).

The setting of acute heart failure (AHF) diagnosis is where the evidence for the use of NPs is most robust. Twenty years after the BNP study using B-type natriuretic peptide (BNP), with similar evidence reported for amino-terminal BNP (NTproBNP), NPs have a central position in international guidelines for the diagnosis of AHF, and have thus been incorporated into the biomarker portfolios of a growing number of hospitals across Europe and the rest of the world.

Given the wealth of evidence, and the consensus in the HF community, one would assume that the use of NPs is widespread and that testing capacity is omnipresent. The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) recently published the first edition of the HFA Atlas. It provides a contemporary description of HF epidemiology, resources, and management, and of the activities of the National Heart Failure Societies (NHFS) in ESC member countries, which comprise a total population of over 800 million people (3). The HFA Atlas identified a median of 3.58 hospitals offering NP measurement in the emergency department per million people. Remarkably however, none of the ESC countries

reported access to NP testing in all its emergency departments. The highest numbers were reported in Germany (with 19.82 hospitals with NPs used in emergency departments per million people), Central Europe, and Scandinavia. The countries with lower use of NPs in emergency departments per million people were Kyrgyzstan and North Macedonia with none, followed by the Russian Federation (with 0.02 hospitals using NPs in emergency departments per million people), with similarly low numbers in other countries from the former Soviet Union and Southeast Europe (Figure 1).

In this viewpoint article, the biomarkers working group of the HFA discusses the scientific evidence that supports the use of NPs to diagnose AHF in the emergency department, followed by the recommendations of international guidelines, and conclude with a call for action to increase awareness to promote equal access to NP analysis in HF diagnosis across Europe.

What does the science say?

BNP production in normal healthy individuals is minimal, with a level of about ≤ 10 pg/mL. In conditions of myocardial stretch, the induction of the BNP gene results in the production and secretion of prohormone proBNP₁₋₁₀₈. This is cleaved into the biologically active BNP₁₋₃₂ (usually referred to as BNP) and the biologically inert but biochemically more stable NTproBNP₁₋₇₆ (usually referred to as NT-proBNP). Both fragments and the precursor, proBNP₁₋₁₀₈, are detected in the circulation (4). The majority of studies regarding the use of B-type class peptides have focused on the measurement of either BNP or NTproBNP.

The study led by Maisel et al. (1) measured BNP levels in 1586 patients presenting to the emergency department with acute dyspnoea. Investigators found that patients with clinically diagnosed AHF had higher BNP levels compared with those

without AHF (mean 675 vs. 110 pg/mL, $P < 0.001$). BNP was the best single predictor of a final diagnosis of AHF compared with individual history, physical examination, chest x-ray, and laboratory findings. The area under the curve (AUC) for BNP in receiver operating characteristic curve testing was 0.91 for the diagnosis of AHF. A cut-off BNP value of 100 pg/mL had a sensitivity of 90% and a specificity of 76%. BNP was more accurate (83%) than either the National Health and Nutrition Examination Survey (NHANES) criteria (67%) or the Framingham criteria (73%), two established sets of criteria for HF diagnosis. Importantly, the best method of AHF diagnosis combined BNP and clinical findings.

NTproBNP is cleared via different mechanisms and has a longer half-life than BNP (70 minutes vs. 20 minutes), but it is equivalent for the diagnostic evaluation of patients with suspected AHF, and likely more accurate in patients treated with neprilysin inhibitors (i.e. sacubitril/valsartan). The use of NTproBNP in the diagnosis of AHF was first demonstrated by Richards et al. (5), and soon confirmed by Bayes-Genis (6) and Januzzi (7). Subsequently, the International Collaborative of NTproBNP (ICON) study (8) examined optimal applications of NTproBNP in 1256 acutely dyspnoeic patients. Patients with AHF had considerably higher NTproBNP concentrations compared with those without AHF (mean 4639 vs. 108 pg/mL, $P < 0.001$), and symptom severity correlated with NTproBNP concentrations ($P = 0.008$). Optimal negative and positive predictive values were obtained by use of an age-independent rule-out cut-off at 300 pg/mL and three age-stratified rule-in cut-off points (NTproBNP ≥ 450 pg/mL for age < 50 years, ≥ 900 pg/mL for age 50-75 years, and ≥ 1800 pg/mL for age > 75 years.). These cut-offs remain equally useful in AHF across the full spectrum of left ventricular ejection fraction. More recently, the ICON RELOADED (ICON: Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency

Department) (9) and BASEL-V (10) studies validated the age-specific NTproBNP cut-offs in contemporary cohorts. They found that the NTproBNP-supported strategy led to 14.5% fewer initial hospitalizations, 16.0% fewer admissions to cardiology, 12.5% fewer admissions to intensive care units, 3.2% fewer ED readmissions, and 21.6% fewer hospital readmissions (11)(Figure 2).

What do the guidelines and the Universal Definition of HF say?

NP testing aids in the diagnosis of AHF, and the use of these biomarkers is now embedded as a class I, level of evidence A, recommendation in ESC and American College of Cardiology/American Heart Association (ACC/AHA) clinical practice guidelines. A Class IA indication is the highest recommendation in international guidelines.

The 2016 guidelines on HF from the ESC (12) state the following: ‘Upon presentation to the emergency department or coronary care unit, a plasma NP level should be measured in all patients with acute dyspnoea and suspected AHF to help in the differentiation of AHF from non-cardiac causes of acute dyspnoea. NPs have high sensitivity, and normal levels in patients with suspected AHF makes the diagnosis unlikely’.

The 2017 focused update of the 2013 guidelines of the ACC/AHA (13) states the following: ‘In emergency settings, NP biomarker levels usually have higher sensitivity than specificity and may be more useful for ruling out than ruling in HF. Although lower values of NP biomarkers exclude the presence of HF, and higher values have reasonably high positive predictive value to diagnose HF, clinicians should be aware that elevated plasma levels for both NPs have been associated with a wide variety of cardiac and noncardiac causes’.

The recent publication of the universal definition of HF proposes the incorporation of an objective measurement (elevated NP levels and/or imaging or haemodynamic derangements) in addition to the symptoms in the HF definition for making the diagnosis of HF more accessible to non-specialists and more reliable and consistent between observers, hospitals, and health care systems (14).

A Call for Action

ESC member countries differ in their organization, delivery, and funding of health care, all of which ultimately lead to the uneven use of NP in the emergency department. With ample and consistent scientific evidence, and the highest recommendation by clinical guidelines, it is time to build strategies to help identify specific barriers to guideline implementation and to define actions to ensure that the majority of patients with acute dyspnoea have access to NP measurement in the emergency department. A timely and accurate diagnosis is crucial to enable early initiation of key lifesaving therapies. NPs should allow clinicians to choose the best diagnostic and treatment strategy more rapidly and to triage patients more confidently.

We present two additional pieces of evidence to support such a call for action initiative. First, the majority of patients are initially diagnosed with HF in the emergency department. An audit of the National Health Service in England showed that 80% of people diagnosed with HF receive the diagnosis following an acute hospital admission, despite half of them having had HF symptoms for up to 5 years before admission (15). Second, the use of NPs has favourable effects not only on health outcomes, but also on costs. Contemporary data show that the use of NTproBNP decreases average inpatient management costs by 10.3% and reduces the total length of stay in the emergency department and hospital (11)(Figure 2).

It is the right time for HFA to launch the “Peptide for Life” initiative (Figure 3) coordinated by the ESC, the HFA, and the NHFS, focused on countries where NP use in the emergency department is currently negligible.

Disclosures: Dr Bayes-Genis reports grants and personal fees from AstraZeneca, Abbott, Vifor, Boehringer-Ingelheim, Novartis, Roche Diagnostics and Critical Diagnostics. The UMCG, which employs Dr. De Boer has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. Dr. de Boer received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche.

Dr Jhund's employer the University of Glasgow has been remunerated by Novartis, Novo Nordisk and AstraZeneca for his work on clinical trials and he has received speakers fees and/or advisory board fees from Novartis, AstraZeneca, Boehringer Ingelheim and grants from Boehringer Ingelheim. Patrick Rossignol reports consulting for Bayer, G3P, Idorsia, and KBP; honoraria from Ablative Solutions, AstraZeneca, Bayer, Boehringer-Ingelheim, Corvidia, CVRx, Fresenius, Grunenthal, Novartis, Novo Nordisk, Relypsa Inc., a Vifor Pharma Group Company, Sanofi, Sequana Medical, Servier, Stealth Peptides, and Vifor Fresenius Medical Care Renal Pharma; Cofounder: CardioRenal.

...

References

- 1- Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med*. 2002 Jul 18;347(3):161-7. doi: 10.1056/NEJMoa020233. PMID: 12124404.
- 2- Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, Coats AJS, Metra M, Mebazaa A, Ruschitzka F, Lainscak M, Filippatos G, Seferovic PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL Jr; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. *Eur J Heart Fail*. 2019 Jun;21(6):715-731. doi: 10.1002/ejhf.1494. PMID: 31222929.
- 3- Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, Polovina M, Gale CP, Lund LH, Lopatin Y, Lainscak M, Savarese G, Huculeci R, Kazakiewicz D, Coats AJS; National Heart Failure Societies of the ESC member countries (see Appendix). The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. *Eur J Heart Fail*. 2021 Feb 26. doi: 10.1002/ejhf.2143. Epub ahead of print. PMID: 33634931.
- 4- Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. *Biochim Biophys Acta*. 2013 Dec;1832(12):2442-50. doi: 10.1016/j.bbadis.2012.12.014. Epub 2013 Jan 9. PMID: 23313577.

- 5- Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. *J Am Coll Cardiol.* 2003 Aug 20;42(4):728-35. doi: 10.1016/s0735-1097(03)00787-3. PMID: 12932611.
- 6- Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, López L, Cotes C, Bellido J, Leta R, Casan P, Ordóñez-Llanos J. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. *Eur J Heart Fail.* 2004 Mar 15;6(3):301-8. doi: 10.1016/j.ejheart.2003.12.013. PMID: 14987580.
- 7- Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. *Am J Cardiol.* 2005 Apr 15;95(8):948-54. doi: 10.1016/j.amjcard.2004.12.032. PMID: 15820160.
- 8- Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. *Eur Heart J.* 2006 Feb;27(3):330-7. doi: 10.1093/eurheartj/ehi631. Epub 2005 Nov 17. PMID: 16293638.
- 9- Januzzi JL Jr, Chen-Tournoux AA, Christenson RH, Doros G, Hollander JE, Levy PD, Nagurney JT, Nowak RM, Pang PS, Patel D, Peacock WF, Rivers EJ, Walters EL, Gaggin HK; ICON-RELOADED Investigators. N-Terminal Pro-B-

- Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study. *J Am Coll Cardiol.* 2018 Mar 20;71(11):1191-1200. doi: 10.1016/j.jacc.2018.01.021. PMID: 29544601.
- 10- Kozhuharov N, Sabti Z, Wussler D, Nowak A, Badertscher P, Twerenbold R, Wildi K, Stallone F, Vogt F, Hilti J, Puelacher C, du Fay de Lavallaz J, Shrestha S, Flores D, Nestelberger T, Koechlin L, Boeddinghaus J, Zimmermann T, Walter J, Schumacher C, Rentsch K, von Eckardstein A, Keller DI, Goudev A, Pfister O, Breidthardt T, Mueller C; BASEL V Investigators. Prospective validation of N-terminal pro B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure. *Eur J Heart Fail.* 2019 Jun;21(6):813-815. doi: 10.1002/ejhf.1471. Epub 2019 Apr 24. PMID: 31020757.
- 11- Siebert U, Milev S, Zou D, Litkiewicz M, Gaggin HK, Tirapelle L, Masson S, Januzzi JL. Economic Evaluation of an N-terminal Pro B-type Natriuretic Peptide-Supported Diagnostic Strategy Among Dyspneic Patients Suspected of Acute Heart Failure in the Emergency Department. *Am J Cardiol.* 2021 May 15;147:61-69. doi: 10.1016/j.amjcard.2021.01.036. Epub 2021 Feb 20. PMID: 33617809.
- 12- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA)

- of the ESC. *Eur J Heart Fail*. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20. PMID: 27207191.
- 13- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*. 2017 Aug 8;136(6):e137-e161. doi: 10.1161/CIR.0000000000000509. Epub 2017 Apr 28. PMID: 28455343.
- 14- Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Felker GM, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Piepoli MF, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by Canadian Heart Failure Society, Heart Failure Association of India, the Cardiac Society of Australia and New Zealand, and the Chinese Heart Failure Association. *Eur J Heart Fail*. 2021 Feb 19. doi: 10.1002/ejhf.2115. Epub ahead of print. PMID: 33605000.

- 15- Bottle A, Kim D, Aylin P, Cowie MR, Majeed A, Hayhoe B. Routes to diagnosis of heart failure: observational study using linked data in England. *Heart*. 2018 Apr;104(7):600-605. doi: 10.1136/heartjnl-2017-312183. Epub 2017 Oct 5. PMID: 28982720.

Figure Legends

Figure 1: Hospitals with availability of natriuretic peptides (BNP or NTproBNP) in the emergency department per million people (taken from Ref #3). Data not available: Belgium, Bulgaria, Czech republic, Italy, Latvia, Poland, Portugal, Republic of Georgia, Spain, Turkey, United Kingdom. No resources: Kyrgyzstan, North Macedonia.

Figure 2: Incorporation of natriuretic peptides in the diagnosis of acute breathlessness results in clinical and economic benefit.

Figure 3: “Peptide for Life” Initiative Logo.

Figure 1




Figure 2




Figure 3

